The Nasdaq Biotechnology Index rose over 2.6%, outperforming the broader US stock market. Among constituents, Sarepta Therapeutics surged 34.98%, Summit Therapeutics Plc. rose 15.53%, Enliven Therapeutics increased 14.06%, Upstream Bio gained 12.07%, Taysha Gene climbed 10.90%, Gossamer Bio advanced 10.61%, and Oruka Therapeutics was up 9.80%. Conversely, Aardvark Therapeutics fell 6.10%, ADMA Biologics dropped 15.23%, Anavex Life Sciences declined 34.61%, and Maze Therapeutics fell 35.24%
The Nasdaq Biotechnology Index closed up over 2.6%, outperforming the broader US stock market index.
Among constituents, Sarepta Therapeutics closed up 34.98%, Summit Therapeutics Plc. rose 15.53%, Enliven Therapeutics increased 14.06%, Upstream Bio gained 12.07%, Taysha Gene climbed 10.90%, Gossamer Bio advanced 10.61%, and Oruka Therapeutics was up 9.80%.
Aardvark Therapeutics closed down 6.10%, ADMA Biologics fell 15.23%, Anavex Life Sciences declined 34.61%, and Maze Therapeutics dropped 35.24%.